May 30, 2017
Off
Advaxis, BMS combining drugs to treat cervical cancer
By Dino MustafićAdvaxis and Bristol-Myers Squibb have announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), as a potential combination treatment option for women with metastatic cervical cancer.